Bliss GVS Pharma Ltd

BSE: 506197

140

total announcements

BLISSGVS.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 15 Oct 2026

Market Cap

₹7,025 Cr

P/E (TTM)

52.4

EPS (TTM)

₹12.60

52W Low

₹118.00

52W High

₹739.90

Dividend Yield

0.22%

Beta

1.22

Price / Book

5.9

Debt / Equity

1.8

Revenue (TTM)

₹1,005 Cr

Gross Margin

53.21%

Operating Margin

23.27%

Announcements Discussion

BSECompany UpdatePromoter Reclassif.14h ago

Bliss GVS Pharma Ltd

Please find enclosed herewith the disclosure under Regulation 31A (10) of the SEBI Regulations in relation to re-classification from the "promoter and promoter Group category" to the "public" category

Bliss GVS Pharma Ltd has re-classified from 'promoter and promoter group' to 'public' category after Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited acquired control of the company. The updated list of promoters and promoter groups is provided.

Read more →📎 1 attachment

BSECompany Update21h ago

Bliss GVS Pharma Ltd

Please find enclosed herewith the newspaper advertisement published regarding the Extension of Special Window for Re-Lodgement of Transfer Requests of Physical Shares.

Bliss GVS Pharma Ltd has published a newspaper advertisement regarding the extension of a special window for re-lodging transfer requests of physical shares, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment

BSECompany UpdateResults6 Oct 2026

Bliss GVS Pharma Ltd

Please find enclosed herewith the certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended September 30, 2026.

Bliss GVS Pharma Ltd has received a certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialisation of securities and listing on stock exchanges.

Read more →📎 1 attachment

BSEInsider Trading / SASTPledge6 Oct 2026

Bliss GVS Pharma Ltd

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

Bliss GVS Pharma Ltd has received a disclosure under Regulation 29(1) of SEBI (SAST) Regulations, 2011, regarding the pledge of 5,09,84,595 equity shares by Catalyst Trusteeship Limited.

Read more →📎 1 attachment

BSEBoard MeetingMgmt Change1 Oct 2026

Bliss GVS Pharma Ltd

Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means.

Bliss GVS Pharma Ltd has approved the adoption of Senior Executive Employee Stock Option Policy 2026 and Employee Stock Option Policy 2026, and granted stock options to employees.

Read more →📎 1 attachment

BSEInsider Trading / SASTM&A1 Oct 2026

Bliss GVS Pharma Ltd

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anupam Rasayan India Ltd

Bliss GVS Pharma Ltd has received a disclosure under Regulation 29(1) of SEBI (SAST) Regulations, 2011, indicating that Anupam Rasayan India Ltd and Mates Visa Consultancy Private Ltd have acquired 47.95% of the company's shares, making them a significant shareholder.

Read more →📎 1 attachment

BSEInsider Trading / SAST29 Sept 2026

Bliss GVS Pharma Ltd

Please find enclosed herewith the Intimation for the Closure of the Trading Window w.e.f. Thursday, October 01, 2026.

Bliss GVS Pharma Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter and half-year ended September 30, 2026.

Read more →📎 1 attachment